Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|September 24, 2018

Risk of Psychosis in Major Depression

Author(s)Brian Miller, MD, PhD, MPH

New findings raise the question of the optimal treatment for prevention of future psychotic depressive episodes.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

TRD: Matching Patients to the Right Treatment

ByMichael E. Thase, MD

August 11th 2026

exercise

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

ByPrerna Gait, MD

August 4th 2026

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

ByGregory Sullivan, MD

July 30th 2026

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

ByGregory Sullivan, MD

July 29th 2026

Neuroplasticity, Novel Targets, and the Future of Depression Pharmacotherapy

Neuroplasticity, Novel Targets, and the Future of Depression Pharmacotherapy

ByJason Kellogg, MD

July 27th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Podcast: Exploring Entactogens With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD